<DOC>
	<DOC>NCT02684370</DOC>
	<brief_summary>This is a randomized double blind, double dummy, placebo and active comparator controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) to support registration for the treatment of moderate to severe chronic plaque psoriasis in adult patients.</brief_summary>
	<brief_title>BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Inclusion criteria: Male or female patients with age &gt;= 18 years at screening. Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug. Have stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis at both Screening and Baseline (Randomisation): Have an involved body surface area (BSA) &gt;= 10% and Have a Psoriasis Area and Severity Index (PASI) score &gt;= 12 and Have a static Physician Global Assessment (sPGA) score of &gt;= 3. Must be candidates for systemic therapy or phototherapy for psoriasis treatment, as assessed by the investigator. Must be a candidate for treatment with Stelara® (ustekinumab) according to local label. Exclusion criteria: Patients with: 1. nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) 2. current druginduced psoriasis (including an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium) 3. active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis that might confound trial evaluations according to investigator's judgment Previous exposure to BI 655066. Previous exposure to ustekinumab (Stelara®).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Skin Diseases</keyword>
	<keyword>Skin Diseases, Papulosquamous</keyword>
	<keyword>ustekinumab</keyword>
	<keyword>Dermatologic Agents</keyword>
	<keyword>ABBV-066</keyword>
	<keyword>BI 655066</keyword>
	<keyword>risankizumab</keyword>
</DOC>